R7E:FRA
Cybin Inc
€6.44
arrow_upward
+6.27%(+0.38) 1D
Jul 17, 10:00:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for R7E...
Open
€5.90
High
€6.44
Low
€5.84
Avg. vol.
604.00
Volume
50.00
52-wk high
€7.95
52-wk low
€3.08
No. of employees
100
Open
€5.90
High
€6.44
Low
€5.84
Avg. vol.
604.00
Volume
50.00
52-wk high
€7.95
52-wk low
€3.08
No. of employees
100
News stories
From sources across the web
TipRanks
·
2 days ago
Helus Pharma Raises US$50 Million to Advance Novel Mental Health Pipeline
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees100
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitehelus.com
AI content may include mistakes. Learn more